PHI receives 46.3 million SEK through rights issue

On July 17, 2018, the subscription period ended in Phase Holographic Imaging PHI AB’s (“PHI”) rights issue to finance marketing, sales growth, and commercial breakthrough with the aim of attracting major industry players. The rights issue was fully subscribed through subscriptions from existing share­holders, the public and guarantee subscribers. PHI will thus receive approximately 46.3 million SEK before rights issuing expenses.

SUBSCRIPTION AND ALLOTMENT

The rights issue of units was subscribed to 43 006 005 SEK including subscriptions commitments, corresponding to a subscription rate of approximately 92.9 %. Guarantee subscription of approxi­mately 3.3 million SEK was thus activated, resulting in that the rights issue was fully subscribed. A total of 1 945 014 new shares are issued. PHI will thus receive approximately 46.3 million SEK before associated expenses of approximately 5.2 million SEK. In addition, a total of 648 338 warrants of series TO 2 are issued, which may additionally raise up to approximately 18.3 million SEK before expenses in May/June 2019. A total of 428 738 units, corresponding to approximately 66 % of the issue volume was subscribed by subscribers with preferential rights. Those who have been allocated units without preferential rights will receive settlement notes, which are scheduled to be issued today July 20, 2018.

NUMBER OF SHARES AND SHARE CAPITAL

When the rights issue has been registered with the Swedish Companies Registration Office, the number of shares in PHI will amount to 13 615 102 and the share capital amounts to 2 723 020.40 SEK. In addition, there are 648 338 outstanding warrants of series TO 2.

TRADING WITH BTU

Trading with BTU (Paid Subscribed Unit) will take place on Spotlight Stock Market until the Swedish Companies Registration Office has registered the rights issue. Registration is expected to occur in the beginning of August 2018.

FINANCIAL ADVISOR

Sedermera Fondkommission is the financial advisor and issuing agent to PHI in connection with the rights issue.

For information about the rights issue, please contact:
Sedermera Fondkommission
Tel: +46 40 615 14 10
E-mail: info@sedermera.se
Web: www.sedermera.se

For additional information, please contact:
Peter Egelberg, CEO

Tel: +46 703 19 42 74
E-mail: ir@phiab.se
Web: www.phiab.se

This information is information that Phase Holographic Imaging is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on July 20, 2018.

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

About Us

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first HoloMonitor instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Head-quartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

Subscribe

Documents & Links